Purchase this article with an account.
Richard W Yee, Brian Wong, Mikhail Lagrimas de Jesus; Topical spironolactone in the treatment of meibomian gland dysfunction. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5664.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The objective of this study was to investigate the effectiveness of topical spironolactone in treating MGD, a major component of dry eye syndrome.
Twenty patients with moderate to severe meibomian gland disease were included in this study. Patients who were taking glaucoma medications, steroid eye drops and other lipid-altering eye drops were excluded from the study. Subjective global dry eye assessment, keratitis and conjunctival staining, anterior blepharitis grade, gland obstruction grade, meibum turbidity grade, meibum viscosity grade, zone A posterior lid margin grade, best corrected vision, and Schirmer‘s score were compared in a pre-post study. Follow-up times ranged from 1 to 7 weeks, with an average of approximately 3 weeks. Statistical analysis was performed using STATA 13 by fitting scored data to a non-parametric model
Patients with moderate to severe MGD had improved self-reported global assessment scores (p = 0.010), turbidity score (p = 0.001), and Zone A scores (p = 0.025) after treatment with topical ophthalmic suspensions of spironolactone.
MGD patients reported improved dry eye symptoms after a week of using spironolactone suspension. The quality of expressed meibum secretions of patients showed improved clarity and viscosity post-treatment. Inflammation decreased at the avascular region posterior to the posterior lid margin post-treatment.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only